Remicade Biosimilars: Samsung Looks To Follow Celltrion's Footsteps
This article was originally published in The Pink Sheet Daily
Executive Summary
351(k) application relies on data extrapolation from Phase III trial in rheumatoid arthritis to support approval across infliximab's indications, including inflammatory bowel disease.
You may also be interested in...
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Merck’s Revised Biosimilar Strategy Poised To Deliver
The big pharma has five biosimilars in Phase III development with its partner Samsung Bioepis, and expects to file them for regulatory approval in 2015 and 2016.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.